New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:44 EDTPTXPernix Therapeutics upgraded at Needham
As previously reported, Needham upgraded Pernix to Strong Buy from Buy. The analyst said Pernix's purchase of Treximet is a "game changer" and should increase short-term profitability and provides an anchor in the CNS market. Price target raised to $10 from $9.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 15, 2015
09:11 EDTPTXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Bsquare (BSQR), up 34.2%... Applied Materials (AMAT), up 3.2%. ALSO HIGHER: Trillium Therapeutics (TRIL), up 13% after being initiated with an Outperform at Oppenheimer... Pernix Therapeutics (PTX), up 7.4% after announcing FDA approval of Treximet for use in pediatric patients... Advaxis (ADXS), up 4.4% after being initiated with a Buy at Jefferies... Netflix (NFLX), up 3.3% following a Bloomberg report that the company is in talks to enter China's online video market... Inovalon (INOV), up 2.9% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: El Pollo LoCo (LOCO), down 12.8%... King Digital (KING), down 8.3%. ALSO LOWER: PlasmaTech (PTBI), down 5.4% after filing to sell 1.93M shares for selling stockholders... Paycom Software (PAYC), down 7% after 8M share Spot Secondary priced at $36.25... Keurig Green Mountain (GMCR), down 5.9% after Keurig Kold investor presentation... 3D Systems (DDD), down 2.4% after CFO transition... Celladon (CLDN), down 5.1% after the CEO says that the company is evaluating strategic options.
07:31 EDTPTXPernix announces FDA approval of Treximet for use in pediatric patients
Pernix Therapeutics Holdings announced that the FDA has approved TREXIMET for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. TREXIMET is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The recommended dose for pediatric patients 12 years of age and older is a single tablet of TREXIMET 10/60 mg per 24-hour period and the maximum recommended dose is 85/500 mg per 24-hour period. The recommended dose for adults is a single tablet of TREXIMET 85/500 mg.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use